4//SEC Filing
Topper James N 4
Accession 0001415889-25-012770
CIK 0001783183other
Filed
May 12, 8:00 PM ET
Accepted
May 13, 4:13 PM ET
Size
13.7 KB
Accession
0001415889-25-012770
Insider Transaction Report
Form 4
Topper James N
Director
Transactions
- Purchase
Common Stock
2025-05-09$3.19/sh+33,376$106,563→ 33,376 total(indirect: By Frazier Life Sciences X, L.P.) - Purchase
Common Stock
2025-05-12$3.04/sh+12,601$38,301→ 48,203 total(indirect: By Frazier Life Sciences X, L.P.) - Purchase
Common Stock
2025-05-09$3.62/sh+2,226$8,053→ 35,602 total(indirect: By Frazier Life Sciences X, L.P.)
Holdings
- 3,912(indirect: By LLC)
Common Stock
- 5,827,415(indirect: By Frazier Life Sciences IX, L.P.)
Common Stock
- 32,096
Common Stock
- 1(indirect: By FHMLS IX, L.L.C)
Common Stock
Footnotes (7)
- [F1]The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $2.575 to $3.57, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in footnote (1) to this Form 4.
- [F2]The shares reported herein are held of record by Frazier Life Sciences X, L.P. FHMLS X, L.P. is the general partner of Frazier Life Sciences X, L.P. and FHMLS X, L.L.C. is the general partner of FHMLS X, L.P. The Reporting Person is one of two managing members of FHMLS X, L.L.C. The Reporting Person disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein.
- [F3]The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $3.58 to $3.75, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in footnote (3) to this Form 4.
- [F4]The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $2.825 to $3.15, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in footnote (4) to this Form 4
- [F5]The shares reported herein are held of record by Frazier Life Sciences IX, L.P. FHMLS IX, L.P. is the general partner of Frazier Life Sciences IX, L.P. and FHMLS IX, L.L.C. is the general partner of FHMLS IX, L.P. The Reporting Person is one of two managing members of FHMLS IX, L.L.C. The Reporting Person disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein.
- [F6]The shares reported herein are held of record by FHMLS IX, L.L.C. The Reporting Person is one of two managing members of FHMLS IX, L.L.C. The Reporting Person disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein.
- [F7]The Reporting Person is a manager of Topper Group III LLC and has voting and investment power of the securities held by Topper Group III LLC.
Documents
Issuer
Phathom Pharmaceuticals, Inc.
CIK 0001783183
Entity typeother
Related Parties
1- filerCIK 0001341382
Filing Metadata
- Form type
- 4
- Filed
- May 12, 8:00 PM ET
- Accepted
- May 13, 4:13 PM ET
- Size
- 13.7 KB